MedTrace Logo

Safety Study of Maraviroc's Effect on Human Osteoclasts

NCT01428986 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2014-09-25

No results posted yet for this study

Summary

This study is to investigate the safety of maraviroc by examining whether there is bone metabolism dysfunction in actual use of maraviroc in human body, or not, measuring bone mineral density and markers for bone formation, desorption and chemokine.

Conditions

  • HIV Infections
  • AIDS

Interventions

DRUG

Maraviroc

Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks

Sponsors & Collaborators

  • National Center for Global Health and Medicine, Japan

    lead OTHER_GOV

Principal Investigators

  • Kenji Yamamoto, MD PhD · Vice Director-General of Research Institute

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2013-03-31
Completion
2014-03-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01428986 on ClinicalTrials.gov